January 30, 2015 3:31 AM ET

Pharmaceuticals

Company Overview of Bluefish Pharmaceuticals AB

Company Overview

Bluefish Pharmaceuticals AB, together with its subsidiaries, develops, manufactures, and markets generic pharmaceuticals in Sweden and internationally. It provides a portfolio of generic pharmaceuticals in various therapeutic areas, such as cardiovascular, central nervous system, gastrointestinal, diabetes, oncology, dermatology, respiratory, inflammatory, genito-urinary, antifungal, antiviral, endocrinology, analgesic, and antibiotics. The company sells its products through a network of independent wholesalers and pharmacies. Bluefish Pharmaceuticals AB was founded in 2005 and is headquartered in Stockholm, Sweden.

Torsgatan 11

Stockholm,  111 23

Sweden

Founded in 2005

90 Employees

Phone:

46 8 51 91 16 00

Fax:

46 8 51 91 16 90

Key Executives for Bluefish Pharmaceuticals AB

Founder
Age: 40
Chief Financial Officer and Member of the Management Group
Age: 43
Member of the Management Group and Chief Executive Officer of Bluefish Global Technology Center
Age: 55
Head of development and Quality Assurance
Director of Bluefish India office
Compensation as of Fiscal Year 2014.

Bluefish Pharmaceuticals AB Key Developments

Bluefish Pharmaceuticals AB Reports Consolidated and Parent Company Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Revenue Guidance for the Fourth Quarter and Full Year of 2014

Bluefish Pharmaceuticals AB reported consolidated and parent company earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the consolidated company reported net sales of SEK 44.671 million against SEK 41.960 million a year ago. Operating loss was SEK 13.027 million against SEK 10.858 million a year ago. Loss after financial items was SEK 14.430 million against SEK 12.644 million a year ago. Loss for the period was SEK 15.133 million against SEK 12.862 million a year ago. Loss per share after dilution was SEK 0.19 against SEK 0.18 a year ago. Cash flow used in operating activities was SEK 16.302 million against cash flow from operating activities of SEK 6.980 million a year ago. LBITDA was SEK 6.9 million against SEK 7.0 million a year ago. For the nine months, the consolidated company reported net sales of SEK 127.477 million against SEK 131.856 million a year ago. Operating loss was SEK 49.658 million against SEK 27.324 million a year ago. Loss after financial items was SEK 53.809 million against SEK 33.406 million a year ago. Loss for the period was SEK 54.873 million against SEK 33.793 million a year ago. Loss per share after dilution was SEK 0.73 against SEK 0.54 a year ago. Cash flow used in operating activities was SEK 34.625 million against cash flow from operating activities of SEK 16.092 million a year ago. LBITDA was SEK 32.7 million against SEK 17.1 million a year ago. For the quarter, the parent company reported net sales of SEK 46.671 million against SEK 41.507 million a year ago. Operating loss was SEK 9.871 million against SEK 10.169 million a year ago. Net loss for the period was SEK 12.066 million against SEK 11.953 million a year ago. For the nine months, the parent company reported net sales of SEK 127.889 million against SEK 130.396 million a year ago. Operating loss was SEK 46.770 million against SEK 26.359 million a year ago. Net loss for the period was SEK 53.175 million against SEK 32.477 million a year ago. The company expects incremental net sales of approximately SEK 15 million in the fourth quarter of 2014. This is equivalent to an increase of 35% compared to fourth quarter of 2013. The company announced that net sales growth for the full year 2014 is expected to be between 5-10%. The incremental sales is estimated to have a positive impact on profitability in the fourth quarter.

Bluefish Pharmaceuticals AB to Report Nine Months, 2014 Results on Nov 14, 2014

Bluefish Pharmaceuticals AB announced that they will report nine months, 2014 results on Nov 14, 2014

Bluefish Pharmaceuticals AB Announces Consolidated and Parent Company Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Sales Guidance for the Fourth Quarter and Full Year of 2014

Bluefish Pharmaceuticals AB announced consolidated and parent company earnings results for the second quarter and six months ended June 30, 2014. For the quarter, on consolidated basis, the company reported net sales of SEK 38,316,000 compared to SEK 43,906,000 a year ago. Operating loss was SEK 21,362,000 compared to SEK 11,761,000 a year ago. Loss after financial items was SEK 22,762,000 compared to SEK 13,253,000 a year ago. Loss or the period was SEK 22,928,000 or SEK 0.32 per basic and diluted share compared to SEK 13,342,000 or SEK 0.23 per basic and diluted share a year ago. LBITDA was SEK 15,044,000 compared to SEK 8,525,000 a year ago. Cash flow from operating activities was SEK 220,000 compared to cash flow used in operating activities of SEK 6,869,000 a year ago. For the six months, on consolidated basis, the company reported net sales of SEK 82,806,000 compared to SEK 89,896,000 a year ago. Operating loss was SEK 36,631,000 compared to SEK 16,466,000 a year ago. Loss after financial items was SEK 39,379,000 compared to SEK 20,762,000 a year ago. Loss or the period was SEK 39,740,000 or SEK 0.55 per basic and diluted share compared to SEK 20,931,000 or SEK 0.36 per basic and diluted share a year ago. LBITDA was SEK 25,731,000 compared to SEK 10,042,000 a year ago. Cash flow used in operating activities was SEK 18,324,000 compared to cash flow from operating activities of SEK 9,112,000 a year ago. For the quarter, the parent company reported net sales of SEK 37,256,000 compared to SEK 43,419,000 a year ago. Operating loss was SEK 21,936,000 compared to SEK 11,609,000 a year ago. Net loss for the period was SEK 23,954,000 compared to SEK 13,108,000 a year ago. For the six months, the parent company reported net sales of SEK 81,218,000 compared to SEK 88,889,000 a year ago. Operating loss was SEK 36,899,000 compared to SEK 16,190,000 a year ago. Net loss for the period was SEK 41,109,000 compared to SEK 20,524,000 a year ago. With several new revenue sources added in the fourth quarter, the company expects incremental net sale of approximately SEK 15 million in fourth quarter of 2014. This is equivalent to an increase of 35% compared to fourth quarter of 2013. Net sales growth for the full year 2014 is expected to be between 5-10%.

Similar Private Companies By Industry

Company Name Region
Wasa Medicals AB Europe
Rechon Life Science AB Europe
Recopharma AB Europe
Calabar AB Europe
Pulmologix AB Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Bluefish Pharmaceuticals AB, please visit www.bluefishpharma.se. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.